#162Extended selection 101–300

Tessa Therapeutics

Singapore · Southeast Asia

Cell and gene therapy

Manufacturing profile

Cell and gene therapy

Country: Singapore

Macro-region: Southeast Asia

Selection basis

The company is placed in positions 101–300 as a manufacturer, biotech, specialty-pharma, generics or CDMO company with practical relevance to the existing FUZKK catalog.

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Representative manufacturing and QC chain

1Starting-material and cell-bank control
2Cell expansion or vector production
3Purification, concentration and formulation
4Identity, viability, potency and qPCR
5Sterility, endotoxin, environmental monitoring and chain of custody

Relevant FUZKK packages

Cell & Gene Therapy / Viral Vector QC Suite

Product/API utilities

Vector Genome Titer q PCR Analyzer Replication Competent Virus RCV Quality Checker Residual Host Cell DNA Quality Checker Residual Host Protein Checker

Lumex — instrumental QC

System Suitability Parameters Checker

LabEx — laboratory QC

Sterility Test Membrane Filtration Quality Checker Bacterial Endotoxins LAL Quality Checker

Medical Devices — equipment and software lifecycle

Supplier Evaluation Checker Calibration Status Checker Process Validation Checker Change Control Impact Checker Requirement Traceability Checker Data Integrity Security Checker

Suggested first pilot

Confirm one real product, method or recurring QC review.
Record the instrument, export format and current specification.
Select 3–7 utilities from the map above.
Run a PASS/FAIL sample and agree the expected output.
After user validation, expand to other products and sites.

Mapping boundary

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Methodology